

#### Consultation on the draft Transparency in Health and Social Care guidance – HDR UK Response.

Health Data Research UK<sup>1</sup> is working to unite the UK's health data to enable discoveries that improve people's lives. Our vision is for large-scale data and advanced analytics to benefit every patient interaction, clinical trial, and biomedical discovery, and to enhance public health.

We are an independent, registered charity with five years of core funding from nine of the UK's leading medical research funders, including UK Research and Innovation, the Department of Health and Social Care in England and equivalents in Northern Ireland, Wales and Scotland, and leading medical research charities. HDR UK is a virtual institute, with staff and partners in all four nations of the UK and an office in central London.

The UK is in a unique position to realise the potential of health data, thanks to the NHS and its cradle-to-grave records for a population of over 65 million people. Safe and secure use of this data could improve treatments, deliver better health care and save lives. It could help tackle some of the biggest health challenges worldwide, including cancer, diabetes, and cardiovascular disease. However, access to this data for researchers is often a lengthy, fragmented process, meaning the potential for improving healthcare is far from being realised in full.

HDR UK is committed to accelerating trustworthy access to health data. By working in partnership with the NHS, industry and universities, we aim to facilitate research to better understand diseases and discover new ways to prevent, treat and cure them. Patients and the public are involved throughout, shaping the Institute's work and ensuring that access to data for research is enabled by safe and secure systems and generates public benefit.

HDR UK welcomes the ICO's draft transparency guidance, as one of our key values is advocating for transparency across all aspects of the health data research ecosystem. Building and maintaining public trust in use of data for research is a HDR UK priority, and trust cannot be earned without transparency.

Our response to the draft guidance draws from our experiences and includes input from our Public Advisory Board, a group of members of the public which who help guide our work and ensure that it is driven by delivering benefits to patients and the public. We have also consulted and incorporated feedback from some members of the UK Health Data Research Alliance ("Alliance")<sup>2</sup> – an independent alliance of over 90 leading health and research organisations. HDR UK convenes the Alliance to establish best practice for the trustworthy and ethical use of UK health data for research at scale.

<sup>&</sup>lt;sup>1</sup> https://www.hdruk.ac.uk/about-us/what-we-do/

<sup>&</sup>lt;sup>2</sup> https://prezi.com/i/view/Kuf20mZFKRvHPvj0LTaP/



The Alliance and PAB in partnership have developed and published Transparency Standards<sup>34</sup> to guide best practice for transparency within data access processes. To encourage adoption of the Transparency Standards, a funding<sup>5</sup>call was run in September 2023 offering awards of up to £15,000 to support individual data custodians with adoption of the Transparency Standards. We received over 24 applications and awarded funding to 19 projects<sup>6</sup> covering a range of approaches to improve accessibility and transparency.

We would be happy to have a discussion about the issues raised in our response.

<sup>&</sup>lt;sup>3</sup> https://zenodo.org/records/8262453

<sup>&</sup>lt;sup>4</sup> <u>Pan-UK Data Governance Steering Group makes progress in improving transparency in processes for accessing health data for research | UKHDRA (ukhealthdata.org)</u>

<sup>&</sup>lt;sup>5</sup> Funding Opportunity to improve transparency in health data access processes for research. | UKHDRA (ukhealthdata.org)

<sup>&</sup>lt;sup>6</sup> New funding awarded to improve transparency of health data access processes for researchers and the public UKHDRA (ukhealthdata.org)





# Consultation on the draft Transparency in Health and Social Care guidance

The Information Commissioner's Office (ICO) is producing guidance on transparency in the health and social care sector.

The draft of this guidance is now published for public consultation.

The draft transparency in health and social care guidance has been developed to help health and social care organisations understand our expectations about transparency.

We are also seeking views on a draft summary impact assessment for this guidance. Your responses will help us understand the code's practical impact on organisations and individuals.

This survey is split into four sections. This covers:

- Section 1: Your views on the draft guidance
- Section 2: Your views on our summary impact assessment
- Section 3: About you and your organisation
- Section 4: Any other comments

The consultation will remain open until 7th January 2024. Please submit responses by 5pm on the 7 January 2024. We may not consider responses received after the deadline.

Please send completed form to <a href="PolicyProjects@ico.org.uk">PolicyProjects@ico.org.uk</a> or print off this document and post to:

Regulatory Policy Projects Team Information Commissioner's Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF



#### **Privacy statement**

For this consultation we may publish the responses received from organisations or a summary of the responses. We will not publish responses from individuals acting in a private capacity. If we do publish any responses, we will remove email addresses and telephone numbers from these responses but apart from this we will publish them in full.

Please be mindful not to share any information in your response which you would not be happy for us to make publicly available.

Should we receive an FOI request for your response we will always seek to consult with you for your views on the disclosure of this information before any decision is made.

For more information about what we do with personal data please see our privacy notice.

## Are you happy to proceed? \*

x I am happy to proceed.

### **Section 1: Your views on the draft guidance**

Answers to the following questions will be helpful in shaping our guidance. Please use the comments boxes to provide further detailed information as far as possible. Some of the questions may not be relevant to you or your organisation, so please skip these as necessary.

<ol> <li>Do you agree that this guidance clearly sets out what is required of health and care organisations to comply with the data protection transparency principle?</li> </ol>
Strongly agree

x AgreeNeither agree nor disagreeDisagreeStrongly disagree

Please provide any comments you have (max. 500 characters):

We are pleased to see the guidance acknowledges that good practice for transparency goes beyond legal requirements. Transparency plays a critical role



in building public trust and confidence in the safe and secure collection and use of data.

It would be helpful to include more detailed, specific, "real world" examples, as the examples given in the draft guidance are very high level and simple. It would also be helpful to link to additional existing resources relevant to transparency (see Q12).

2(a). Do you agree that this guidance provides a clear definition of transparency and privacy information?
Strongly agree  x Agree  Neither agree nor disagree  Disagree  Strongly disagree
Please provide any comments you have (max. 500 characters):  We would welcome an explicit acknowledgement in the section "How does this guidance approach transparency?" that whilst the distinction between transparency and privacy information is based on legal requirements, members of the public often see them as being equally important and may expect the "could" standards to be met by any responsible organisation.
We found the definition of "Transparency information" somewhat unclear and would suggest the following changes:
This describes the total range of material you <b>should</b> provide to comply with th transparency principle, together with additional information that you <b>could</b> provide to people to make your transparency material more effective
2(b). Does the distinction between transparency information and privacy information make sense to you?
X Yes  No Unsure
Please provide any comments you have (max. 500 characters):

Members of our public advisory board (PAB), who help guide work at Health Data Research UK (HDR UK) and ensure that it is driven by delivering benefits to patients and the public, felt that the guidance positioned transparency information as being less important than privacy information. As noted above,



clarification that transparency information and privacy information are often viewed by the public as being equally important would be welcome.

informat	u agree that this guidance provides useful additional ion to the Health & Social Care sector that is not part of our guidance on the principle of transparency and the right to be
	Strongly agree
X	Agree Neither agree nor disagree
	Disagree
	Strongly disagree
As noted understar	ovide any comments you have (max. 500 characters): above, more detailed case studies and examples would assist in and implementation of the guidance. More examples related to be would be helpful.
this guida and socia understar be inform saying "Y	that front line health and social care staff are not included under "who ance is for", however we would suggest that staff working in the NHS of care settings who interact with the public should have an ending of and training in the principles of transparency and the right to need. We note that the ICO Accountability Framework supports this, four organisation can demonstrate that any member of front-line staff is explain the necessary privacy information to data subjects and provide ."
to organis	note that the guidance uses "you" rather than being framed as applying sations / data controllers which is a different approach to other ICO  It would be helpful to make clear under "who is this guidance for" sparency is ultimately an organisational responsibility.
guidance transpare	d welcome creation of an "easy read" plain language version of the suitable for a lay audience, to support better public understanding of ency and the right to he informed and to educate those working in d social care who are less familiar with the topic.
	u agree that this guidance is balanced between the separate health and social care?
Too f	focused on health
_ Too f	focused on social care

Health [	Data Research UK
	About right
	X Not enough information on either
	Unsure / don't know
	Please provide any comments you have (max. 500 characters):  In our view it would be helpful to include more specific worked examples relevant to social care, noting that there are a large number of smaller organisations in social care (e.g. care homes) and these organisations may not have significant legal or information governance resources available. We would also suggest adding a specific statement in the section "who is this guidance for" clarifying that it applies to care homes and other providers of social care services.  For both health and social care, more detailed, specific, "real world" examples are needed as the examples given in the draft guidance are very high level and simple.
	guidance clearly defines the ICO's expectations in the legislative requirements section and that the terms are applied consistently throughout the guidance?
	Strongly agree
	X Agree
	Neither agree nor disagree
	Disagree
	Strongly disagree
	Please provide any comments you have (max. 500 characters):  Members of our PAB expressed concern that "should" and "could" requirements feel "optional" in the guidance which risks creating a misconception that minimum requirements are acceptable and/or only the "must" requirements are needed. We would therefore suggest that an explicit statement is added under the heading "What is a legal requirement in this guidance and what is good practice?" clarifying that for the "should" and "could" requirements there may be different ways to comply with the law, but the transparency requirements are
	not optional and best practice is strongly encouraged.  It would also be helpful to delineate between "must", "should" and "could" more clearly e.g. with a table with "must" "should" "could" headings in each section

6. Do you agree with the definitions we have provided on openness and honesty? Are the examples of how you can demonstrate that you are

and an overall summary table at the end.



# being open and honest useful and accurate in the context of health and care?

care	?
X A	Strongly agree Agree Neither agree nor disagree Disagree Strongly disagree e provide any comments you have (max. 500 characters):
As no unde	oted above, more specific and detailed case studies would aid rstanding of the guidance. "Open" and "Honest" are subjective terms and to quantify.
sugge in sor duty	e section "Data Opt-Outs" under "How should we reflect choice?" we would est adding a link to more information about the opt-out and clarifying that me cases the opt-out "must" be applied to comply with the common law (even if not mandated by data protection laws): :://digital.nhs.uk/services/national-data-opt-out
orga trans	you agree with that the section on harms is useful for nisations when considering the risks of failing to provide sufficient sparency material?  Strongly agree
	Agree
	Neither agree nor disagree
	Disagree
	Strongly disagree
Please	e provide any comments you have (max. 500 characters):
	example given is helpful in explaining the risks of not reaching all sections

The example given is helpful in explaining the risks of not reaching all sections of the public via appropriate channels. We would welcome the addition of a further example highlighting the risks of not properly engaging the public so that the public understand and trust how their data is going to be used. The GPDPR programme (currently paused) could be referenced as a 'real life" example of this in practice; the impact on public trust of the project during the summer of 2021 can clearly be seen in the publicly available opt-outs dashboard. A loss of public trust, at least in part due to a lack of effective public engagement, resulted in a large number of opt-outs over a period of a few months: https://digital.nhs.uk/dashboards/national-data-opt-out-open-data.

We would also strongly encourage the ICO to make clear in the guidance that being transparent about the benefits of using data to public health, as well as the risks, can promote trust e.g.: https://cprd.com/examples-how-research-



using-cprd-data-benefits-public-health

- PEDRI- Best Practice Standards

8. Do you agree that the section on patient engagement provides useful information to help organisations develop transparency information that responds to people's needs and priorities?		
Strongly agree  X Agree  Neither agree nor disagree  Disagree  Strongly disagree  Please provide any comments you have (max. 500 characters):  The section on patient engagement is useful in prompting organisations to think of different and more innovative ways of communicating transparency information, particularly through focusing on the patients' needs/priorities. We have the following suggestions for improving and clarifying the content of this section:		
<ul> <li>The reference to a "bus stop" advertisement as a "method of public communications which let people know about how you use their information" is potentially unhelpful and we would suggest removing it. It would be very difficult to convey this type of information in a "one glance" advert.</li> <li>The guidance gives the example of a letter as a direct communication method, we would suggest amending this to say, "e.g. a letter, email or text message". Email and text message are also key direct communication methods and can be very effective.</li> <li>We would suggest including case studies authored by members of the public who have experienced successful and unsuccessful patient engagement to bring the public voice into the guidance. There are many patient engagement initiatives that have taken place and HDR UK would be pleased to discuss further with the ICO how members of the public could contribute to case studies. By way of example, public contributors who shape and influence the work of HDR UK have contributed to videos and blogs about their experiences here: https://www.hdruk.ac.uk/about-us/involving-and-engaging-patients-and-the-public/get-involved/hdr-uk-stories/</li> </ul>		
Links to the following best practice guidance on patient engagement could also be added to the guidance:		

UK Standard for Public Involvement- Learning for Involvement



sets out clearly how organisations should approach the delivery of transparency and privacy information?
<ul><li>Strongly agree</li><li>X Agree</li></ul>
Neither agree nor disagree
Disagree
Strongly disagree
Please provide any comments you have (max. 500 characters):
See response to Qu 8 above. Additional case studies authored with members of the public would be a very helpful addition to this section of the guidance.
10. Do you agree that the transparency checklist provides a useful summary of the guidance and a mechanism to assess an organisation's transparency level?
summary of the guidance and a mechanism to assess an organisation's
summary of the guidance and a mechanism to assess an organisation's transparency level?
summary of the guidance and a mechanism to assess an organisation's transparency level?  Strongly agree
summary of the guidance and a mechanism to assess an organisation's transparency level?  Strongly agree Agree X Neither agree nor disagree
summary of the guidance and a mechanism to assess an organisation's transparency level?  Strongly agree Agree X Neither agree nor disagree Disagree
summary of the guidance and a mechanism to assess an organisation's transparency level?  Strongly agree Agree X Neither agree nor disagree Disagree Strongly disagree

9. Do you agree that the section on providing transparency information

11. Have you identified any aspects of the guidance that you feel are inaccurate or any areas we have missed or not covered sufficiently?

If so, please provide further details.

It is not clear whether public and patient opinions on the guidance are being actively sought by the ICO and we would welcome clarification of this. If specific engagement with the public on the guidance has not yet been carried out, we would suggest an extension to the consultation end date and a focus on direct public engagement before the guidance is finalised.



In addition, awareness of the guidance in the health data research sector appears to be low and with the deadline for responses coming just after the Christmas break this may hinder broad feedback to the consultation. We would therefore suggest that an extension of the 7 January deadline should be considered in any event.

12. We have provided placeholders for case studies and examples in the guidance to further illustrate certain issues relating to: Public trust in use or sharing of health and social care information; Harms associated with transparency and the impacts on patients and service users; Providing easily understandable information to patients and service users on complex forms of data processing; and Organisations working together to develop a 'joined-up' approach to the delivery of transparency information. Do you have any examples of good practice relating to these topics? Would you like to provide these to the ICO to be summarised and included in the guidance?

We would be happy to discuss the following examples with the ICO for inclusion in the guidance:

<u>Transparency Standards</u> co-created by the Pan-UK Data Governance Steering Group (a sub-working Group of the UK Health Data Research Alliance) and members of the public. These standards set out good practice for being transparent with the public about how researchers can apply to access and use data and how data is used:

- The Standards are published here: https://zenodo.org/records/8262453
- More information on the standards is published here: https://ukhealthdata.org/news/pan-uk-data-governancesteering-group-makes-progress-in-improving-transparency-inthe-use-of-health-data-for-research/

<u>Data Use Register Standard</u> published by the UK Health Data Research Alliance, which sets out recommendations for a data use register standard to be adopted by organisations responsible for the safe sharing of data used for research and innovation. A data use register is a public record of how data is being used for research, by who and for what purpose and is a critical element of transparency:

https://zenodo.org/records/5902743#.YfAI 7P2Uk

<u>Building trust in data access through public involvement in governance:</u> Survey findings and recommendations from HDR UK's Public Advisory Board are published here:

 https://www.hdruk.ac.uk/wp-content/uploads/2021/07/280621-PAB-Data-Access-procedures-paper-Building-trust-in-dataaccess-through-public-involvement-in-governance.pdf



If so, please provide your name and email address below and we may contact you to discuss further.

Section 2: Your views on our summary impact assessment	
The following questions are about our impact assessment. Some of may not be relevant to you or your organisation so please skip the necessary, or as indicated in the descriptions.	
We are seeking views on our impact assessment summary table, we provided as supporting evidence for the consultation. This sets our overview of the types of impacts that we have considered.	
We will consider the proportionality of further assessment of the in move towards final publication of the guidance.	ipacts as we
13. To what extent do you agree that the impact assessmen table adequately scopes the main affected groups and associmpacts of the guidance?	
Strongly agree  X Agree  Neither agree nor disagree  Disagree  Strongly disagree	
If you answered disagree, strongly disagree or unsure/don't know, provide further examples of affected groups or impacts we may ha require further consideration. (max. 500 characters)	•
N/A	
14. Can you provide us with any further evidence for us to cour impact assessment?	onsider in
Yes No	



If you answered Yes, please could you provide the impact evidence or a link to it in the box below, or contact details where we can reach you to discuss further. (max. 500 characters)
Please see response to Qu. 12 above.
15. Please provide any further comments or suggestions you may have about the impact assessment summary table.
In the "cost-benefit analysis" section under "Wider Society" the following sentence is potentially misleading:
"Potential for wider benefits such as improved data for research purposes as a result of individuals being better informed, and potentially more willing to consent to their personal data being processed."
As the guidance rightly notes, consent under UK GDPR is rarely the appropriate lawful basis in the context of health and care information. In our view it would be more accurate to say:
"Potential for wider benefits such as improved data for research purposes as a result of individuals being better informed, and less likely to opt out of their personal data being processed."
16. Are you acting on behalf of an organisation?
X Yes No
Section 3: About you and your organisation
To further assist our consultation process, it would be useful to know some details about you. Your information will be processed in accordance with our privacy notice.
17. Are you answering as: (tick all that apply)
An organisation or person processing health data
<ul> <li>A representative of a professional, industry or trade association</li> <li>An organisation representing the interests of patients in health settings (eg GP practice, hospital trust)</li> </ul>

/	
Data	Research UK
	An organisation representing the interests of patients in social care setting (eg care home)
	A trade union
	An academic
X	Other (please specify):
	HDR UK is the national institute for health data science, a charity working to unite the UK's health data to enable discoveries that improve people's lives.
18.	Please specify the name of your organisation (optional):
Не	alth Data Research UK
19.	How would you describe your organisation's size?
	0 to 9 members of staff
Χ	10 to 249 members of staff
	250 to 499 members of staff
	500 or more members of staff
ma	If you work in a health or social care providing organisation, how ny patients or care users is your organisation responsible for
NI/	proximately)?
N/	proximately)?
21. pro	Who in your organisation needs to read the guidance? Please wide job titles or roles, rather than names.
21. pro	who in your organisation needs to read the guidance? Please
21. pro	Who in your organisation needs to read the guidance? Please wide job titles or roles, rather than names.
21. pro	Who in your organisation needs to read the guidance? Please wide job titles or roles, rather than names.
21. pro	Who in your organisation needs to read the guidance? Please wide job titles or roles, rather than names.  ead of Legal, Trust & Ethics  To what extent (if at all) do data protection issues affect strategic
21. pro	Who in your organisation needs to read the guidance? Please wide job titles or roles, rather than names.  Ead of Legal, Trust & Ethics  To what extent (if at all) do data protection issues affect strategic siness decisions within your organisation?
21. pro	Who in your organisation needs to read the guidance? Please wide job titles or roles, rather than names.  Ead of Legal, Trust & Ethics  To what extent (if at all) do data protection issues affect strategic siness decisions within your organisation?  Data protection is a major feature in most of our decision making
21. pro	Who in your organisation needs to read the guidance? Please wide job titles or roles, rather than names.  Ead of Legal, Trust & Ethics  To what extent (if at all) do data protection issues affect strategic siness decisions within your organisation?  Data protection is a major feature in most of our decision making Data protection is a major feature but only in specific circumstances



cost(s) or burden(s) to your organisation benefit(s) to your organisation both X neither unsure / don't know
24. Could you please describe the types of additional costs or benefits your organisation might incur?
N/A
25. Can you provide an estimate of the costs or benefits your organisation is likely to incur and briefly how you have calculated these?
N/A
N/A  26. Please provide any further comments or suggestions you may have about how the guidance might impact your organisation?

23. Do you think the guidance set out in this document presents

**Section 4: Any other comments** 

This section is for any other comments on our guidance or impact assessment that have not been covered elsewhere.



Do you have any other comments you would like to make?	
N/A	